伊普森在2026年AACR会议上分享了针对坚固的实体瘤新型癌症免疫疗法的前临床成果. Ipsen shared promising preclinical results for new cancer immunotherapies targeting tough solid tumors at the 2026 AACR meeting.

在2026年AACR年度会议上,Ipsen 提出了其早期免疫瘤学管道的临床前数据,强调了针对癌症免疫疗法的新途径的有希望的候选人. At the 2026 AACR Annual Meeting, Ipsen presented preclinical data on its early-stage immuno-oncology pipeline, highlighting promising candidates that target novel pathways in cancer immunotherapy. 该公司强调了这些疗法在难以治疗的固体瘤中改善结果的潜力,其结果显示动物模型中的T细胞激活和瘤回归得到增强. The company emphasized the potential of these therapies to improve outcomes in hard-to-treat solid tumors, with results showing enhanced T-cell activation and tumor regression in animal models. 伊普森指出,其研发项目包括两种特异性抗体和工程细胞疗法等创新方法,为未来的临床开发提供了有利位置. Ipsen noted that its pipeline includes innovative approaches such as bispecific antibodies and engineered cell therapies, positioning them for future clinical development. 这些数据强调了该公司日益关注新一代癌症治疗的发展. The data underscored the company’s growing focus on advancing next-generation cancer treatments.